OBJECTIVE: Granulocyte colony-stimulating factor (G-CSF) in combination with plerixafor produces significant mobilization of CD34(+) cells in rhesus macaques. We sought to evaluate whether these CD34(+) cells can stably reconstitute blood cells with lentiviral gene marking. MATERIALS AND METHODS: We performed hematopoietic stem cell transplantation using G-CSF and plerixafor-mobilized rhesus CD34(+) cells transduced with a lentiviral vector, and these data were compared with those of G-CSF and stem cell factor mobilization. RESULTS: G-CSF and plerixafor mobilization resulted in CD34(+) cell yields that were twofold higher than yields with G-CSF and stem cell factor. CD123 (interleukin-3 receptor) expression was greater in G-CSF and plerixafor-mobilized CD34(+) cells when compared to G-CSF alone. Animals transplanted with G-CSF and plerixafor-mobilized cells showed engraftment of all lineages, similar to animals who received G-CSF and stem cell factor-mobilized grafts. Lymphocyte engraftment was accelerated in animals receiving the G-CSF and plerixafor-mobilized CD34(+) cells. One animal in the G-CSF and plerixafor group developed cold agglutinin-associated skin rash during the first 3 months of rapid lymphocyte recovery. One year after transplantation, all animals had 2% to 10% transgene expression in all blood cell lineages. CONCLUSIONS: G-CSF and plerixafor-mobilized CD34(+) cells accelerate lymphocyte engraftment and contain hematopoietic stem cell capable of reconstituting multilineage blood cells. These findings indicate important differences to consider in plerixafor-based hematopoietic stem cell mobilization protocols in rhesus macaques. Published by Elsevier Inc.
OBJECTIVE:Granulocyte colony-stimulating factor (G-CSF) in combination with plerixafor produces significant mobilization of CD34(+) cells in rhesus macaques. We sought to evaluate whether these CD34(+) cells can stably reconstitute blood cells with lentiviral gene marking. MATERIALS AND METHODS: We performed hematopoietic stem cell transplantation using G-CSF and plerixafor-mobilized rhesus CD34(+) cells transduced with a lentiviral vector, and these data were compared with those of G-CSF and stem cell factor mobilization. RESULTS:G-CSF and plerixafor mobilization resulted in CD34(+) cell yields that were twofold higher than yields with G-CSF and stem cell factor. CD123 (interleukin-3 receptor) expression was greater in G-CSF and plerixafor-mobilized CD34(+) cells when compared to G-CSF alone. Animals transplanted with G-CSF and plerixafor-mobilized cells showed engraftment of all lineages, similar to animals who received G-CSF and stem cell factor-mobilized grafts. Lymphocyte engraftment was accelerated in animals receiving the G-CSF and plerixafor-mobilized CD34(+) cells. One animal in the G-CSF and plerixafor group developed cold agglutinin-associated skin rash during the first 3 months of rapid lymphocyte recovery. One year after transplantation, all animals had 2% to 10% transgene expression in all blood cell lineages. CONCLUSIONS:G-CSF and plerixafor-mobilized CD34(+) cells accelerate lymphocyte engraftment and contain hematopoietic stem cell capable of reconstituting multilineage blood cells. These findings indicate important differences to consider in plerixafor-based hematopoietic stem cell mobilization protocols in rhesus macaques. Published by Elsevier Inc.
Authors: Neeltje A Kootstra; Carsten Munk; Nina Tonnu; Nathaniel R Landau; Inder M Verma Journal: Proc Natl Acad Sci U S A Date: 2003-01-23 Impact factor: 11.205
Authors: Robert E Donahue; Ping Jin; Aylin C Bonifacino; Mark E Metzger; Jiaqiang Ren; Ena Wang; David F Stroncek Journal: Blood Date: 2009-07-14 Impact factor: 22.113
Authors: Peiman Hematti; Sascha Tuchman; Andre Larochelle; Mark E Metzger; Robert E Donahue; John F Tisdale Journal: Stem Cells Date: 2004 Impact factor: 6.277
Authors: Yoo-Jin Kim; Yoon-Sang Kim; Andre Larochelle; Gabriel Renaud; Tyra G Wolfsberg; Rima Adler; Robert E Donahue; Peiman Hematti; Bum-Kee Hong; Jean Roayaei; Keiko Akagi; Janice M Riberdy; Arthur W Nienhuis; Cynthia E Dunbar; Derek A Persons Journal: Blood Date: 2009-04-01 Impact factor: 22.113
Authors: Leslie S Kean; Sharon Sen; Olusegun Onabajo; Karnail Singh; Jennifer Robertson; Linda Stempora; Aylin C Bonifacino; Mark E Metzger; Daniel E L Promislow; Joseph J Mattapallil; Robert E Donahue Journal: Blood Date: 2011-10-11 Impact factor: 22.113
Authors: Naoya Uchida; Atsushi Fujita; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale Journal: Hum Gene Ther Clin Dev Date: 2017-04-17 Impact factor: 5.032
Authors: Kate Stringaris; Robert F Hoyt; Jan K Davidson-Moncada; Jeremy M Pantin; John F Tisdale; Naoya Uchida; Lydia N Raines; Robert Reger; Noriko Sato; Cynthia E Dunbar; Timothy J Hunt; Randall R Clevenger; Allen Krouse; Mark E Metzger; Aylin C Bonifacino; William Telford; Peter L Choyke; Theresa Engels; Robert E Donahue; Richard W Childs Journal: Blood Adv Date: 2020-12-22
Authors: Sandhya R Panch; Yu Ying Yau; Elizabeth M Kang; Suk See De Ravin; Harry L Malech; Susan F Leitman Journal: Transfusion Date: 2014-08-21 Impact factor: 3.157
Authors: Peter L Choyke; Richard W Childs; Noriko Sato; Kate Stringaris; Jan K Davidson-Moncada; Robert Reger; Stephen S Adler; Cynthia Dunbar Journal: Clin Cancer Res Date: 2020-02-07 Impact factor: 12.531
Authors: Naoya Uchida; Phillip W Hargrove; Coen J Lap; Molly E Evans; Oswald Phang; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Anh-Dao Nguyen; Matthew M Hsieh; Tyra G Wolfsberg; Robert E Donahue; Derek A Persons; John F Tisdale Journal: Mol Ther Date: 2012-08-07 Impact factor: 11.454
Authors: Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem Journal: Blood Adv Date: 2018-05-08